Latest filing published 14 Nov 2022 for Glycomimetics INC, €6,696.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Armand Girard: trading record in brief
Armand Girard (senior executive) discloses dealings in Crescent Biopharma, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 20 January 2021 and the latest from 11 November 2022.
The open-market side counts 1 purchase for €6,696 alongside 1 sale for €2,339. On balance, insiders were net buyers of €4,357. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant. Since January 2022: 1 purchase and 1 sale on the market.
The latest filing, published on 14 November 2022, reports an open-market purchase of €6,696 in Crescent Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Armand Girard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,500 shares@ US$1.0574.1% of flowCommon StockSEC:0001209191-22-056563:0Canonical exit: 9 Feb 2023 (T+90)
- 2,339 shares@ US$1.0925.9% of flowCommon StockSEC:0001209191-22-017968:0
2 of 2 declarations
